Increased mortality for neurological and mental diseases following early bilateral oophorectomy

Neuroepidemiology

Volumn 33, Issue 1, 2009, Pages 32-40

  Rivera, Cathleen M ^a   Grossardt, Brandon R ^a   Rhodes, Deborah J ^a   Rocca, Walter A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cohort study; Mental diseases; Mortality; Neurological diseases; Oophorectomy

Indexed keywords

ESTROGEN;

ADULT; AGE; ARTICLE; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; DEATH CERTIFICATE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MENTAL DISEASE; MORTALITY; NEUROLOGIC DISEASE; OVARIECTOMY; UNITED STATES;

ADOLESCENT; ADULT; CAUSE OF DEATH; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYSTERECTOMY; INFANT; MENTAL DISORDERS; NERVOUS SYSTEM DISEASES; OVARIECTOMY; PREMENOPAUSE; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; YOUNG ADULT;

EID: 64149083457     PISSN: 02515350     EISSN: None     Source Type: Journal    
DOI: 10.1159/000211951     Document Type: Article

References (38)

1. Rocca WA, Bower JH, Maraganore DM, Ahlskog JE, Grossardt BR, de Andrade M, Melton LJ 3rd: Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology 2007;69:1074-1083.
2. Rocca WA, Bower JH, Maraganore DM, Ahlskog JE, Grossardt BR, de Andrade M, Melton LJ 3rd: Increased risk of parkinsonism in women who underwent oophorectomy before menopause. Neurolog y 2008;70: 200-209.
3. Rocca WA, Grossardt BR, Maraganore DM: The long-term effects of oophorectomy on cognitive and motor aging are age dependent. Neurodegener Dis 2008;5:257-260.
4. Shuster LT, Gostout BS, Grossardt BR, Rocca WA: Prophylactic oophorectomy in premenopausal women and long-term health. Menopause Int 2008;14:111-116.
5. Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, Fillit H, Stefanick ML, Hendrix SL, Lewis CE, Masaki K, Coker LH: Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004;291:2947-2958.
6. Rocca WA, Grossadt BR, de Andrade M, Malkasian GD, Melton LJ 3rd: Survival patternsafter oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol 2006;7:821-828.
7. Porta MS, International Epidemiological Association: A Dictionary of Epidemiology, ed 5. Oxford, Oxford University Press, 2008.
8. Rocca WA, Grossardt BR, Geda YE, Gostout BS, Bower JH, Maraganore DM, de Andrade M, Melton LJ 3rd: Long-term risk of depressive and anxiety symptoms after early bilateral oophorectomy. Menopause 2008;15: 1050-1059.
9. Rocca WA, Shuster LT, Grossardt BR, Maraganore DM, Gostout BS, Geda YE, Melton LJ 3rd: Long-term effects of bilateral oophorectomy on brain aging: unanswered questions from the Mayo Clinic Cohort Study of Oophorectomy and Aging. Womens Health (London) 2009;5:39-48.
10. Melton LJ 3rd, Bergstralh EJ, Malkasian GD, O'Fallon WM: Bilateral oophorectomy trends in Olmsted County, Minnesota, 1950-1987. Epidemiology 1991;2:149-152.
11. Melton LJ 3rd, Crowson CS, Malkasian GD, O'Fallon WM: Fracture risk following bilateral oophorectomy. J Clin Epidemiol 1996; 49:1111-1115.
12. Melton LJ 3rd, Khosla S, Malkasian GD, Achenbach SJ, Oberg AL, Riggs BL: Fracture risk after bilateral oophorectomy in elderly women. J Bone Miner Res 2003;18:900-905.
13. Beard CM, Crowson CS, Malkasian GD, O'Fallon WM, Melton LJ 3rd: Cardiovascular disease and cancer risk following bilateral oophorectomy: a population-based study in Rochester, Minnesota. J Womens Health 1995;4:133-141.
14. Melton LJ 3rd: History of the Rochester Epidemiology Project. Mayo Clin Proc 1996; 71:266-274.
15. Commission on Professional and Hospital Activities: H-ICDA, Hospital Adaptation of ICDA, ed 2. Ann Arbor, 1973.
16. Therneau TM, Grambsch PM: Modeling Survival Data: Extending the Cox Model. New York, Springer, 2000.
17. Armstrong K, Schwartz JS, Randall T, Rubin SC, Weber B: Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis. J Clin Oncol 2004;22:1045-1054.
18. Weisskopf MG, O'Reilly EJ, McCullough ML, Calle EE, Thun MJ, Cudkowicz M, Ascherio A: Prospective study of military service and mortality from ALS. Neurology 2005;64:32-37.
19. Buckley J, Warlow C, Smith P, Hilton-Jones D, Irvine S, Tew JR: Motor neuron disease in England and Wales, 1959-1979. J Neurol Neurosurg Psychiatry 1983;46:197-205.
20. Chio A, Magnani C, O ddenino E, Tolardo G, Schiffer D: Accuracy of death certificate diagnosis of amyotrophic lateral sclerosis. J Epidemiol Community Health 1992;46:517-518.
21. Hoffman PM, Brody JA: The reliability of death certificate reporting for amyotrophic lateral sclerosis. J Chronic Dis 1971;24:5-8.
22. Smith R, Studd JW: A pilot study of the effect upon multiple sclerosis of the menopause, hormone replacement therapy and the menstrual cycle. J R Soc Med 1992;85:612-613.
23. Holmqvist P, Wallberg M, Hammar M, Landtblom AM, Brynhildsen J: Symptoms of multiple sclerosis in women in relation to sex steroid exposure. Maturitas 2006;54:149-153.
24. Voskuhl RR: Hormone-based therapies in MS. Int MS J 2003;10:60-66.
25. Sicotte NL, Liva SM, Klutch R, Pfeiffer P, Bouvier S, Odesa S, Wu TC, Voskuhl RR: Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann Neurol 2002;52:421-428.
26. Houtchens MK: Pregnancy and multiple sclerosis. Semin Neurol 2007;27:434-441.
27. Morrison JH, Brinton RD, Schmidt PJ, Gore AC: Estrogen, menopause, and the aging brain: how basic neuroscience can inform hormone therapy in women. J Neurosci 2006;26:10332-10348.
28. Gibbs RG: Long-term treatment with estrogen and progesterone enhances acquisition of a spatial memory task by ovariectomized aged rats. Neurobiol Aging 2000;21:107-116.
29. Webber KM, Casadesus G, Marlatt MW, Perry G, Hamlin CR, Atwood CS, Bowen RL, Smith MA: Estrogen bows to a new master: the role of gonadotropins in Alzheimer pathogenesis. Ann N Y Acad Sci 2005;1052: 201-209.
30. Singh M: Progesterone-induced neuroprotection. Endocrine 2006;29:271-274.
31. Singh M, Sumien N, Kyser C, Simpkins JW: Estrogens and progesterone as neuroprotectants: what animal models teach us. Front Biosci 2008;13:1083-1089.
32. Brinton RD, Thompson RF, Foy MR, Baudry M, Wang J, Finch CE, Morgan TE, Pike CJ, Mack WJ, Stanczyk FZ, Nilsen J: Progesterone receptors: form and function in brain. Front Neuroendocrinol 2008;29:313-339.
33. Bialek M, Zaremba P, Borowicz KK, Czuczwar SJ: Neuroprotective role of testosterone in the nervous system. Pol J Pharmacol 2004; 56:509-518.
34. Beard CM, Melton LJ 3rd, Cedel SL, Richelson LS, Riggs BL: Ascertainment of risk factors for osteoporosis: comparison of interview data with medical record review. J Bone Miner Res 1990;5:691-699.
35. Coulam CB, Adamson SC, Annegers JF: Incidence of premature ovarian failure. Obstet Gynecol 1986;67:604-606.
36. Marks NF, Shinberg DS: Socioeconomic status differences in hormone therapy. Am J Epidemiol 1998;148:581-593.
37. Grodstein F, Clarkson TB, Manson JE: Understanding the divergent data on post-menopausal hormone therapy. N Engl J Med 2003;348:645-650.
38. Lynch JW, Kaplan GA, Cohen RD, Tuomilehto J, Salonen JT: Do cardiovascular risk factors explain the relation between socioeconomic status, risk of all-cause mortality, cardiovascular mortality, and acute myocardial infarction? Am J Epidemiol 1996; 144:934-942.